SEC Form 4 · accession 0001479290-18-000114
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Cyril Allouche
Officer — Principal Accounting Officer
Period of report
Nov 9, 2018
Accepted (ET)
Nov 9, 2018 · 8:59 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 9, 2018 | M | 2,188 | $13.35 | A | 6,938 | D | |
| Common Stock | Nov 9, 2018 | S | 2,188 | $23.72 | D | 4,750 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $13.35 | Nov 9, 2018 | M | 2,188 | D | — | Oct 30, 2026 | Common Stock | 2,188 | 7,500 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Allouche.
- F2The Option vests in accordance to the following schedule: 25% on the first anniversary of the vesting commencement date of October 31, 2016, and 1/48th vesting each month thereafter for the remaining three years, subject to Mr. Allouche's Continuous Service (as defined in the Plan) as of such date.